Journal of Bone Oncology

Papers
(The TQCC of Journal of Bone Oncology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Separation surgery for metastatic epidural spinal cord compression: A qualitative review43
New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma38
Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis37
Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review37
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer31
Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways27
Targeting ferroptosis in osteosarcoma25
Current strategies for the treatment of solitary and aneurysmal bone cysts: A review of the literature24
Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group24
The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer23
Malignancy in giant cell tumor of bone in the extremities23
Potential diagnostic value of miRNAs in peripheral blood for osteosarcoma: A meta-analysis23
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval22
The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone20
Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma18
Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review17
Neurological outcomes after surgery for spinal metastases in symptomatic patients: Does the type of decompression play a role? A comparison between different strategies in a 10-year experience17
Luteolin attenuates the chemoresistance of osteosarcoma through inhibiting the PTN/β-catenin/MDR1 signaling axis by upregulating miR-38417
Osteoporosis management in hematologic stem cell transplant recipients: Executive summary16
Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal co16
LncRNA SNHG16 promotes epithelial-mesenchymal transition by upregulating ITGA6 through miR-488 inhibition in osteosarcoma16
Sensory nerves: A driver of the vicious cycle in bone metastasis?16
Role of microRNAs in the crosstalk between osteosarcoma cells and the tumour microenvironment16
ceRNA network development and tumour-infiltrating immune cell analysis of metastatic breast cancer to bone16
Prediction of the early recurrence in spinal giant cell tumor of bone using radiomics of preoperative CT: Long-term outcome of 62 consecutive patients15
Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic: GEMO position paper15
Primary bone lymphoma: Clinical presentation and therapeutic considerations15
The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties14
Periacetabular reconstruction following limb-salvage surgery for pelvic sarcomas14
The inhibition of MARK2 suppresses cisplatin resistance of osteosarcoma stem cells by regulating DNA damage and repair14
In vitro three-dimensional cell cultures for bone sarcomas14
Giant cell tumor of bone: A single center study of 115 cases13
MiR-451a promotes cell growth, migration and EMT in osteosarcoma by regulating YTHDC1-mediated m6A methylation to activate the AKT/mTOR signaling pathway13
One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma12
Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis11
c-Met expression in renal cell carcinoma with bone metastases11
Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin11
Development and validation of a cuproptosis-related lncRNA model correlated to the cancer-associated fibroblasts enable the prediction prognosis of patients with osteosarcoma11
Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial11
Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer11
Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey10
Primary perivascular epithelioid cell tumor (PEComa) in bone: A review of the literature and a case arising in the humerus with multiple metastases10
Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of WHO fracture risk assessment tool (FRAX) and bone mineral density in real-life clinical pr10
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?10
Surgical outcomes of metastatic bone tumors in the extremities (Surgical outcomes of bone metastases)10
Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature10
External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring mod10
ELF1-activated FOXD3-AS1 promotes the migration, invasion and EMT of osteosarcoma cells via sponging miR-296-5p to upregulate ZCCHC310
All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma10
Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report10
Delay in diagnosis of primary osteosarcoma of bone in children: Have we improved in the last 15 years and what is the impact of delay on diagnosis?9
Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices9
Bone metastases from urothelial carcinoma. The dark side of the moon9
von Willebrand factor promotes platelet-induced metastasis of osteosarcoma through activation of the VWF-GPIb axis9
Clinical course of grafted cartilage in osteoarticular frozen autografts for reconstruction after resection of malignant bone and soft-tissue tumor involving an epiphysis9
Epidemiology and detection of cement leakage in patients with spine metastases treated with percutaneous vertebroplasty: A 10-year observational study9
Heterogeneity of chondrosarcomas response to irradiations with X-rays and carbon ions: A comparative study on five cell lines9
Identifying biomolecules and constructing a prognostic risk prediction model for recurrence in osteosarcoma9
Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations9
Chondroblastoma: Is intralesional curettage with the use of adjuvants a sufficient way of therapy?9
Pre-operative prognostic nutritional index was associated with recurrence after surgery in giant cell tumor of bone patients8
Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy – Observational prospective single institution analysis8
A predictive biomarker panel for bone metastases: Liquid biopsy approach8
Long non-coding RNA BLACAT1 expedites osteosarcoma cell proliferation, migration and invasion via up-regulating SOX12 through miR-6088
m6A-dependent upregulation of TRAF6 by METTL3 is associated with metastatic osteosarcoma8
BAIAP2L2 promotes the proliferation, migration and invasion of osteosarcoma associated with the Wnt/β-catenin pathway8
Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma8
Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target8
Lipopolysaccharide-binding protein expression is associated to the metastatic status of osteosarcoma patients8
Autocrine motility factor and its receptor expression in musculoskeletal tumors8
Hsa_circ_0010220 regulates miR-198/Syntaxin 6 axis to promote osteosarcoma progression8
Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach8
CircRERE confers the resistance of multiple myeloma to bortezomib depending on the regulation of CD47 by exerting the sponge effect on miR-152-3p8
Optimization of a syngeneic murine model of bone metastasis8
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis7
Chemotherapy in the management of periosteal osteosarcoma: A narrative review7
Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer – a retrospective cohort study7
The patterns of distant metastasis and prognostic factors in patients with primary metastatic Ewing sarcoma of the bone7
EFEMP1 binds to STEAP1 to promote osteosarcoma proliferation and invasion via the Wnt/β-catenin and TGF-β/Smad2/3 signal pathways7
Down-regulation of circular RNA hsa_circ_0007534 suppresses cell growth by regulating miR-219a-5p/SOX5 axis in osteosarcoma7
Differential diagnostic value of 18F-FDG PET/CT in osteolytic lesions7
Effects of different levels of TGF-β expression and tumor cell necrosis rates in osteosarcoma on the chemotherapy resistance of osteosarcoma7
Long-non-coding RNA RUSC1-AS1 accelerates osteosarcoma development by miR-101-3p-mediated Notch1 signalling pathway7
Does vitamin D deficiency predict tumour malignancy in patients with bone tumours? Data from a multi-center cohort analysis7
Evaluation of local and circulating osteopontin in malignant and benign primary bone tumors7
The minimally invasive endoscopic technique for the treatment of symptomatic benign bone lesions: Preliminary results from a retrospective study7
0.021825075149536